Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Published:2020-07 Issue:1 Volume:72 Page:58-71
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Patel Keyur¹,Harrison Stephen A.²,Elkhashab Magdy³,Trotter James F.⁴,Herring Robert⁵,Rojter Sergio E.⁶,Kayali Zeid⁷,Wong Vincent Wai‐Sun⁸^ORCID,Greenbloom Susan⁹,Jayakumar Saumya¹⁰,Shiffman Mitchell L.¹¹,Freilich Bradley¹²,Lawitz Eric J.¹³,Gane Edward J.¹⁴,Harting Eliza¹⁵,Xu Jun¹⁵,Billin Andrew N.¹⁵,Chung Chuhan¹⁵,Djedjos C. Stephen¹⁵,Subramanian G. Mani¹⁵,Myers Robert P.¹⁵,Middleton Michael S.¹⁰,Rinella Mary¹⁶,Noureddin Mazen¹⁷

Affiliation:

1. University of Toronto Toronto ON Canada

2. Pinnacle Clinical Research San Antonio TX

3. Toronto Liver Center Toronto ON Canada

4. Texas Digestive Disease Consultants Dallas TX

5. Quality Medical Research Nashville TN

6. Ruane Clinical Research Los Angeles CA

7. Inland Empire Liver Foundation Rialto CA

8. Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong Hong Kong

9. Toronto Digestive Disease Associates Woodbridge ON Canada

10. University of California San Diego San Diego CA

11. Bon Secours Mercy Health Richmond VA

12. Kansas City Research Institute Kansas City MO

13. Texas Liver Institute University of Texas Health San Antonio San Antonio TX

14. Liver Unit Auckland City Hospital Auckland New Zealand

15. Gilead Sciences, Inc. Foster City CA

16. Feinberg School of Medicine Northwestern University Chicago IL

17. Cedars‐Sinai Medical Center Los Angeles CA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31205

Reference31 articles.

1. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

2. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

3. Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications

4. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

5. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

Cited by 234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Computational study of novel natural agonists targeting farnesoid X receptor;Scientific Reports;2024-07-30

3. New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease;Cell & Bioscience;2024-07-06

4. Immunology of bile acids regulated receptors;Progress in Lipid Research;2024-07

5. Sarmentol H derived from Sedum sarmentosum Bunge directly targets FXR to mitigate cholestasis by recruiting SRC-1;Phytomedicine;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3